Svetlana Lucas, Chief Business Officer at Scribe Therapeutics, Inc. (SCTX), bought 3,000 shares at $15.00 ($45K) on 2026-07-23, disclosed to the SEC on 2026-07-27.
Chief Business Officer Svetlana Lucas purchased 3,000 shares for $45,000 at $15.00, marking the largest insider purchase in the company's history. This significant buy signals confidence in the stock's post-IPO momentum and the company's genetic editing pipeline.
The stock is currently trading at $18.86, representing an 8.61% premium to its 52-week low of $17.365, though it remains down 25.47% from its 52-week high of $25.305.
1) Q3 earnings on 2026-10-28; 2) Scribe's Genetic Editing Aims to Prevent Heart Attacks (Barrons.com, 2026-07-30) regarding the $125 million IPO proceeds funding clinical trials; 3) Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO (GuruFocus.com, 2026-07-24) citing a $440.3 million valuation.
The stock is currently trading 25.47% below its 52-week high of $25.305, indicating significant room for downside if the market revisits its valuation following the recent surge.
Nothing distinguishes this filing.